Koers Claritas Pharmaceuticals Toronto S.E.
Aandelen
KLY
CA1806341071
Biotechnologie & Medisch Onderzoek
Omzet 2019 | - | Omzet 2020 | - | Marktkapitalisatie | 13,65 mln. 18,68 mln. 12,69 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2019 | -21 mln. -28,74 mln. -19,52 mln. | Nettowinst (verlies) 2020 | 4 mln. 5,47 mln. 3,72 mln. | EV/omzet 2019 | - |
Nettoschuld 2019 | 704K 963K 654K | Nettoschuld 2020 | 920K 1,26 mln. 855K | EV/omzet 2020 | - |
K/w-verhouding 2019 |
-0,9
x | K/w-verhouding 2020 |
3,17
x | Werknemers | - |
Dividendrendement 2019 * |
-
| Dividendrendement 2020 |
-
| Vrij verhandelbaar | 99,74% |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,69% | 47,86 mld. | |
+46,90% | 41,42 mld. | |
-3,46% | 40,66 mld. | |
-6,20% | 28,92 mld. | |
+9,17% | 25,55 mld. | |
-20,42% | 19,27 mld. | |
+0,17% | 12,15 mld. | |
+28,07% | 12,14 mld. | |
-1,24% | 11,99 mld. |